Ovoca Bio Regulatory News (OVB)

OVOCA CONSENTS TO THE MIGRATION OF ITS ORDINARY SHARES

TO THE EUROCLEAR BANK CENTRAL SECURITIES DEPOSITORY

AND

MIGRATION OF PARTICIPATING SECURITIES EXPECTED TO TAKE EFFECT ON 15 MARCH 2021

Ovoca Bio PLC (the "Company") provides the following update in relation to the migration of Irish corporate securities from CREST to Euroclear Bank ("Migration") under the Migration of Participating Securities Act 2019 ("2019 Act").

All resolutions necessary to facilitate participation of the Company's ordinary shares in Migration were approved at the extraordinary general meeting of the Company held on 16 February 2021 ("EGM").

In accordance with Resolution 1 approved at the EGM, the board of directors of the Company has approved the Company giving its consent to the migration of its ordinary shares to the Euroclear Bank SA/NV central securities depository in accordance with the Migration of Participating Securities Act 2019. The requisite notifications in connection with the migration have also been made by the Company to the Irish Companies Registration Office and Euronext Dublin. The Company has now completed all necessary actions required of it under the 2019 Act and the Migration Guide.

Euronext Dublin has published a statement on the dedicated web page relating to its obligations under the 2019 Act. This statement can be found at the following website address: https://www.euronext.com/en/migration-csd-services-for-irish-securities-crest-euroclear-bank

This statement is to the effect that Migration under the 2019 Act is scheduled to proceed in accordance with the indicative timetable which was previously communicated to the market, most recently on 17 February 2021. In particular Euronext Dublin has advised that the Live Date on which Migration is to take effect is 15 March 2021 and further that, subject to final testing by market participants expected to take place on the afternoon of Friday, 12 March, this date will be formally appointed by Euronext Dublin as the Live Date for Migration on the evening of Friday, 12 March 2021 when Euronext Dublin will make the order confirming the Live Date as Monday, 15 March 2021 and will upload the order to the website mentioned above.

Accordingly, no change is anticipated in relation to the timetable set out in the Company's EGM Circular in respect of Migration.

The Company does not intend to issue any further updates on Migration as it affects the Company before Migration, save to the extent that there is a material change to the information previously provided.

Defined terms used in this announcement have the same meaning as set out in the Company's Circular to Shareholders dated 25 January 2021.

End

For further information:

Ovoca Bio plc

Kirill Golovanov (Chief Executive)

Tel +353 1 661 9819

info@ovocabio.com

Davy (Nominated Adviser, Euronext Growth Advisor and Broker)

John Frain / Daragh O'Reilly

Tel: +353 1 679 6363

Consilium Strategic Communications

Chris Gardner, Chris Welsh, Carina Jurs

ovocabio@consilium-comms.com

Tel: +44 (0)20 3709 5700

About Ovoca Bio

Ovoca Bio is a European-based biopharmaceutical company with a focus on women's health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD).

The Company's lead product, BP-101, a novel synthetic peptide administered through a nasal spray, is clinically validated, with Phase II and Phase III studies conducted in Russia demonstrating statistically significant improvement in a number of key efficacy outcomes, including an increase in female sexual desire and reduction of symptoms of distress associated with HSDD.

Ovoca Bio is seeking to develop the drug for major global markets - in particular the United States and Europe, as well as obtain marketing approval in the Russian Federation.